DOCSLIB.ORG

Coagulation Factor Xa (Arachidonic Acid/Factor V Antibody/Thrombin) A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Coagulation Factor Xa (Arachidonic Acid/Factor V Antibody/Thrombin) A Proc. Nati. Acad. Sci. USA Vol. 80, pp. 6086-6090, October 1983 Medical Sciences Inhibition of thromboxane A2 synthesis in human platelets by coagulation factor Xa (arachidonic acid/factor V antibody/thrombin) A. KUMAR SINHA, A. KONETI RAO, JANET WILLIS, AND ROBERT W. COLMAN Thrombosis Research Center and Hematology-Oncology Section of the Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140 Communicated by Oscar D. Ratnoff, June 23, 1983 ABSTRACT Factor X. binds to platelets provided that factor with platelets that leads to the efficient formation of thrombin Va is present on the platelet surface, an interaction that results in from prothrombin, a concomitant effect of this binding of factor a striking acceleration of the conversion of prothrombin to throm- Xa is the inhibition of TXA2 synthesis in these cells. Because bin. Thrombin then initiates fibrin formation, induces platelet ag- TXA2 is a platelet-aggregating agent and a potent vasoconstric- gregation, and stimulates the intraplatelet synthesis of throm- tor, the inhibition of TXA2 synthesis by factor Xa would provide boxane A2 (TXA2). Addition of thrombin (2.4-14.4 nM) to platelet- negative feedback control of the synthesis of TXA2 in platelets. rich plasma increased the basal level of TXA2, measured as thromboxane B2, from <0.5 pmol per 108 platelets to (mean + MATERIALS AND METHODS SEM) 100 ± 22 and 250 ± 10 pmol per 108 platelets, respectively. Treatment of platelet-rich plasma with increasing concentrations Chemicals and Reagents. [1-`4C]Arachidonic acid (55.8 mCi/ of factor X. (1-12 nM) prior to the addition of thrombin pro- mmol; 1 Ci = 3.7 x 1010 Bq) and [5,6,8,9,11,12,14,15-3H(N)] gressively inhibited the production of TXA2. Thrombin (9.6 nM), thromboxane B2 (TXB2) (100 Ci/mmol) were purchased from which produced 93% of the maximal formation of TXA2, was in- New England Nuclear. [5,6,8,11,12,14,15-3H(N)]Prostaglan- hibited 70% by factor Xa (10 nM). To identify which of these steps ,din E2 (PGE2) (160 Ci/mmol) was bought from Amersham. Di- in thromboxane synthesis was inhibited by factor Xa, platelets la- isopropyl fluorophosphate (iPr2P-F) was bought from Sigma. beled with [14C]arachidonic acid were exposed to thrombin and Antisera to PGE2 was obtained from Miles. All other chemicals products of prostaglandin synthesis were separated by thin-layer used were of analytical grades. chromatography. In contrast to the inhibition of TXA2 synthesis, Coagulation Factors. Bovine factor X was prepared by the prostaglandin E2 and prostaglandin F2a synthesis were not inhib- method of Bajaj and Mann (5). The purified factor X was ac- ited suggesting that neither phospholipase(s) nor cycloxygenase was tivated by using the Russell's viper venom and the resulting involved. The inhibition of TXA2 formation by factor Xa could be factor Xa purified according to Jesty and Esnouf (6). Polyacryl- reversed by increasing the molar ratio of thrombin to factor Xa amide gel (8.6%) electrophoresis of factor Xa in the presence to 5.5. Incubation of platelets with an IgG fraction of a human of dithiothreitol showed the presence of three bands corre- monoclonal antifactor V antibody, previously shown to inhibit fac- sponding to heavy chain of aXa (Mr = 34,500), heavy chain of tor X. binding, was found to block factor Xa inhibition of TXA2 synthesis. The inhibition of TXA2 synthesis requires the presence (3Xa (Mr = 29,500), and light chain of I3Xa (Mr = 16,000) (7), of the active site serine of factor Xa and is not specific for TXA2 the major component accounting for 95%. The prepared factor formation induced by thrombin because it is also demonstrable Xa had a specific activity of 5,500 units per mg of protein de- when the agonist is ADP. Further, factor Xa does not require ad- termined according to Cole et al. (8). The molarity of factor Xa ditional plasma components for its action because its inhibitory was obtained by adding the molecular weights of heavy chain effects are detected in gel-filtered platelets. The effect of factor of PXa and the light chain (Mr = 45,000). Xa was evident at physiological (1.3 mM) calcium concentrations. Both bovine factors X and Xa were also obtained from Sigma. These results indicate that factor X. binding to platelets through Factor X was found to be a single component (Mr = 54,000) on factor Va not only stimulates thrombin formation but also has a 8.6% polyacrylamide gel electrophoresis in NaDodSO4 (0.1%) countervailing effect by inhibiting TXA2 formation. but in the absence of reducing agent. The specific activity of factor X was 100-150 units/mg of protein. Factor Xa used had The interaction of blood coagulation factor Xa with the human a specific activity of 4,000-5,000 units/mg of protein. Poly- platelet surface in the presence of Ca2" accelerates the gen- acrylamide gel electrophoresis of factor Xa in the presence of eration of thrombin from prothrombin at a rate 300,000 times NaDodSO4 and dithiothreitol showed the presence ofthree bands faster than the rate observed with factor Xa in solution (1). Fac- corresponding to the heavy chain of aXa (Mr = 34,500, 10%), tor Xa binding to platelets requires the presence of factor Va, heavy chain of /3Xa (Mr = 29,500, 90%), and light chain (Mr = which may be derived by release from platelets (1) from its in- 16,000). Except that the commercial factor Xa was somewhat tracellular site, the a granules (2), by agonists such as thrombin. less active than the proteinase prepared as described above, the Alternatively, exogenous factor Va produced by the action of enzyme was essentially identical in both preparations. thrombin on plasma factor V (3) facilitates factor Xa binding in Human thrombin was purified by the method of Fenton et a coordinate manner. In addition to these two actions of throm- al. (9) by using commercial thrombin as the starting material bin on platelets and factor V, respectively, thrombin is also a from Sigma. The purified material was a homogenous protein potent inducer of thromboxane A2 (TXA2) synthesis in these in gel electrophoresis and had a specific activity of 2,480 units/ cells (4). mg. The molarity of the thrombin preparation was calculated We now report that in addition to the interaction of factor Xa from the molecular weight of the enzyme, Mr 33,500. The publication costs of this article were defrayed in part by page charge Abbreviations: TXA2, thromboxane A2; TXB2, thromboxane B2; PGF2a, payment. This article must therefore be hereby marked "advertise- prostaglandin F2a; PGE2, prostaglandin E2; iPr2P-F, diisopropyl fluo- ment" in accordance with 18 U.S.C. §1734 solely to indicate this fact. rophosphate; RIA, radioimmunoassay. 6086 Downloaded by guest on September 26, 2021 Medical Sciences: Sinha et al. Proc. Natl. Acad. Sci. USA 80 (1983) 6087 iPr2P-F-inactivated factor Xa was prepared by incubating 1.0 Antifactor V Antibody. Antifactor V antibody used in these mg of factor Xa, prepared as above, in 25 mM Tris'HCl buffer studies was a IgG fraction of a human monoclonal IgG4 A an- (pH 8.0) with 15 mM iPr2P-F in a total volume of 0.5 ml for 2.5 tifactor V antibody (19) kindly supplied by Helen Glueck (Uni- hr at 370C as described by Leveson and Esnouf (10). Treatment versity of Cincinnati). An IgG fraction prepared by (NH4)2SO4 of factor Xa by iPr2P-F does not result in total loss of activity, precipitation and DEAE-Sephadex chromatography of the an- but under these conditions we found that factor Xa lost >85% tibody was prepared and furnished by H. C. Chiu (Thrombosis of its original activity. The reaction mixture was then dialyzed Research Center). Approximately 40 Mg of the IgG fraction per against 0.15 M NaCl for 16 hr at 40C. ml neutralized >99% offactorV activity in 1 ml of normal plasma. Human factor X was prepared according to DiScipio et al. (11), was activated and purified as described above (6), and had RESULTS a specific activity of 4,000 units/mg of protein. Stimulation of TXA2 Formation by Thrombin. Addition of Platelet Preparation. All blood donors had not taken any increasing concentrations of thrombin to platelet-rich plasma medication at least 2 wk before blood donation. Venous blood induced the synthesis of higher levels of platelet TXA2, as de- was collected through siliconized needles into plastic syringes; termined by RIA of TXB2 (Fig. 1). Although as little as 0.2 unit coagulation was prevented by mixing 9 vol of blood with 1 vol of thrombin per ml (2.4 nM) would aggregate 80% of the plate- of trisodium citrate (final concentration, 13 mM). Platelet-rich lets (not shown), the formation of TXB2 continued to increase, plasma was obtained by centrifugation of samples for 10 min at up to a thrombin concentration of 14.4 nM. The basal level of 170 x g. The supernatant platelet-rich plasma (2-3 X 10' cells TXB2 (<0.5 pmol per 108 platelets) increased -300-fold (100 per ml) was collected. Platelet counts were performed in a ± 22 pmol per 108 cells; mean ± SEM) and 800-fold (250 ± 10 Coulter Counter model ZB equipped with a 50-Mum aperture pmol per 108 cells) in the presence of 2.4 nM and 14.4 nM tube. Gel-filtered platelets were prepared as described (12). thrombin, respectively. The labeling of gel-filtered platelets with [I4C]serotonin and its Inhibition of TXB2 Production by Factor Xa. When platelet- release were studied according to Walsh et al. (13). rich plasma was treated with 9.6 nM thrombin, the TXA2 level Platelet Aggregation Studies.
Load more

Recommended publications
  • MONONINE (“Difficulty ® Monoclonal Antibody Purified in Concentrating”; Subject Recovered)
    CSL Behring IU/kg (n=38), 0.98 ± 0.45 K at doses >95-115 IU/kg (n=21), 0.70 ± 0.38 K at doses >115-135 IU/kg (n=2), 0.67 K at doses >135-155 IU/kg (n=1), and 0.73 ± 0.34 K at doses >155 IU/kg (n=5). Among the 36 subjects who received these high doses, only one (2.8%) Coagulation Factor IX (Human) reported an adverse experience with a possible relationship to MONONINE (“difficulty ® Monoclonal Antibody Purified in concentrating”; subject recovered). In no subjects were thrombo genic complications MONONINE observed or reported.4 only The manufacturing procedure for MONONINE includes multiple processing steps that DESCRIPTION have been designed to reduce the risk of virus transmission. Validation studies of the Coagulation Factor IX (Human), MONONINE® is a sterile, stable, lyophilized concentrate monoclonal antibody (MAb) immunoaffinity chromatography/chemical treatment step and of Factor IX prepared from pooled human plasma and is intended for use in therapy nanofiltration step used in the production of MONONINE doc ument the virus reduction of Factor IX deficiency, known as Hemophilia B or Christmas disease. MONONINE is capacity of the processes employed. These studies were conducted using the rel evant purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of enveloped and non-enveloped viruses. The results of these virus validation studies utilizing immunoaffinity chromatography. A murine monoclonal antibody to Factor IX is used as an a wide range of viruses with different physicochemical properties are summarized in Table affinity ligand to isolate Factor IX from the source material.
    [Show full text]
  • The Rare Coagulation Disorders
    Treatment OF HEMOPHILIA April 2006 · No. 39 THE RARE COAGULATION DISORDERS Paula HB Bolton-Maggs Department of Haematology Manchester Royal Infirmary Manchester, United Kingdom Published by the World Federation of Hemophilia (WFH) © World Federation of Hemophilia, 2006 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s web site at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel. : (514) 875-7944 Fax : (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org The Treatment of Hemophilia series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or to consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph. Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff.
    [Show full text]
  • Activated Protein C Resistance: the Most Common Risk Factor for Venous Thromboembolism
    J Am Board Fam Pract: first published as 10.3122/15572625-13-2-111 on 1 March 2000. Downloaded from CLINICAL REVIEW Activated Protein C Resistance: The Most Common Risk Factor for Venous Thromboembolism Dawn R. Sheppard, DO Background: Venous thromboembolism is a major cause of morbidity and mortality. Although activated protein C resistance (APC-R) is the most commonly recognized inherited risk factor for venous throm­ boembolism, little is known about its long-tenn implications on health. Methods: MEDLINE was searched from January 1989 through August 1999 using the key words ''thromboembolism," ''thrombosis," "activated protein C resistance," and "factor V Leiden." Results: One in 1000 people in the United States is affected by venous thromboembolism annually. APC-R is now understood to be responsible for up to 64% of these cases. APC-R, which occurs widely in some ethnic groups and is nearly absent in others, is due to a single point mutation in the gene for clot­ ting factor V. As a result, inactivation of factor V by activated protein C is impaired, leading to a hyper­ coagulable state. This condition creates a lifelong increased risk of thrombosis and, possibly, anticoag- ulant therapy.. Conclusion: Family physicians have a new tool for assessing risks for venous thromboembolism. Recognizing that up to 64% of patients with venous thromboembolism can have APe-R and treating this disorder with prophylactic and therapeutic anticoagulation might reduce patient morbidity and mortal­ ity from venous thromboembolism. Screening high-risk patients might now be indicated. (J Am Board Fam Pract 2000i13:111-5.) Venous thromboembolism, a serious health prob­ "thromboembolism," "thrombosis," "activated pro­ lem and an important cause of morbidity, affects tein C resistance," and "factor V Leiden." about 1 in 1000 persons annually.
    [Show full text]
  • Familial Multiple Coagulation Factor Deficiencies
    Journal of Clinical Medicine Article Familial Multiple Coagulation Factor Deficiencies (FMCFDs) in a Large Cohort of Patients—A Single-Center Experience in Genetic Diagnosis Barbara Preisler 1,†, Behnaz Pezeshkpoor 1,† , Atanas Banchev 2 , Ronald Fischer 3, Barbara Zieger 4, Ute Scholz 5, Heiko Rühl 1, Bettina Kemkes-Matthes 6, Ursula Schmitt 7, Antje Redlich 8 , Sule Unal 9 , Hans-Jürgen Laws 10, Martin Olivieri 11 , Johannes Oldenburg 1 and Anna Pavlova 1,* 1 Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, 53127 Bonn, Germany; [email protected] (B.P.); [email protected] (B.P.); [email protected] (H.R.); [email protected] (J.O.) 2 Department of Paediatric Haematology and Oncology, University Hospital “Tzaritza Giovanna—ISUL”, 1527 Sofia, Bulgaria; [email protected] 3 Hemophilia Care Center, SRH Kurpfalzkrankenhaus Heidelberg, 69123 Heidelberg, Germany; ronald.fi[email protected] 4 Department of Pediatrics and Adolescent Medicine, University Medical Center–University of Freiburg, 79106 Freiburg, Germany; [email protected] 5 Center of Hemostasis, MVZ Labor Leipzig, 04289 Leipzig, Germany; [email protected] 6 Hemostasis Center, Justus Liebig University Giessen, 35392 Giessen, Germany; [email protected] 7 Center of Hemostasis Berlin, 10789 Berlin-Schöneberg, Germany; [email protected] 8 Pediatric Oncology Department, Otto von Guericke University Children’s Hospital Magdeburg, 39120 Magdeburg, Germany; [email protected] 9 Division of Pediatric Hematology Ankara, Hacettepe University, 06100 Ankara, Turkey; Citation: Preisler, B.; Pezeshkpoor, [email protected] B.; Banchev, A.; Fischer, R.; Zieger, B.; 10 Department of Pediatric Oncology, Hematology and Clinical Immunology, University of Duesseldorf, Scholz, U.; Rühl, H.; Kemkes-Matthes, 40225 Duesseldorf, Germany; [email protected] B.; Schmitt, U.; Redlich, A.; et al.
    [Show full text]
  • Regulation of Coagulation by the Fibrinolytic System: Expecting the Unexpected
    Bleeding disorders Regulation of coagulation by the fibrinolytic system: expecting the unexpected K.A. Hajjar ABSTRACT Department of Cell and Recent investigations into fibrinolysis and coagulation have yielded exciting and unexpected findings. Developmental Biology, Of note, deficiencies of the major components of the classical fibrinolytic system, namely plasminogen, Department of Pediatrics tissue plasminogen activator, and urokinase, are now recognized to be rare causes of macrovascular Department of Medicine, thrombosis. At the same time, both plasminogen activator excess and fibrinolytic inhibitor deficiencies Weill Cornell Medical College, are associated with clinically significant bleeding, while elevated inhibitor levels, particularly thrombin New York, New York, USA activatable fibrinolysis inhibitor, appear to confer clinically significant risk for thrombosis. Receptor- mediated cell surface fibrinolysis adds a new dimension to the regulation of fibrin balance. Exaggerated expression of the annexin A2 complex, for example, is associated with hemorrhage in acute promyelo- Hematology Education: cytic leukemia, whereas autoantibodies directed against A2 correlate with thrombotic disease in the education program for the patients with antiphospholipid syndrome. The contributions of the urokinase receptor and a diverse annual congress of the European array of plasminogen receptors to fibrin homeostasis remain to be defined. Future studies are likely to Hematology Association reveal novel mechanisms that co-regulate coagulation and
    [Show full text]
  • The Two Faces of Thrombosis: Coagulation Cascade and Platelet Aggregation. Are Platelets the Main Therapeutic Target
    Thrombosis and Circulation Open Access Cimmino et al., J Thrombo Cir 2017, 3:1 Review Article Open Access The Two Faces of Thrombosis: Coagulation Cascade and Platelet Aggregation. Are Platelets the Main Therapeutic Target? Giovanni Cimmino*, Salvatore Fischetti and Paolo Golino Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, University of Campania “Luigi Vanvitelli”, Naples, Italy *Corresponding author: Giovanni Cimmino, MD, PhD, Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, University of Campania “Luigi Vanvitelli”, via Leonardo Bianchi, 180131 Naples, Italy. Tel: +39-081-7064175, Fax: +39-081-7064234; E-mail: [email protected] Received date: Dec 28, 2016, Accepted date: Jan 27, 2017, Published date: Jan 31, 2017 Copyright: © 2017 Giovanni C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Acute thrombus formation is the pathophysiological substrate underlying several clinical conditions, such as acute coronary syndrome (ACS) and stroke. Activation of coagulation cascade is a key step of the thrombotic process: vessel injury results in exposure of the glycoprotein tissue factor (TF) to the flowing blood. Once exposed, TF binds factor VII/VIIa (FVII/FVIIa) and in presence of calcium ions, it forms a tertiary complex able to activate FX to FXa, FIX to FIXa, and FVIIa itself. The final step is thrombin formation at the site of vessel injury with subsequent platelet activation, fibrinogen to fibrin conversion and ultimately thrombus formation. Platelets are the key cells in primary hemostasis.
    [Show full text]
  • Alpha-Dystroglycan Plays Functional Roles in Platelet Aggregation and Thrombus Growth
    Alpha-dystroglycan plays functional roles in platelet aggregation and thrombus growth by Reid Gallant A thesis submitted in conformity with the requirements For the degree of Master of Science Graduate Department of Laboratory Medicine and Pathobiology University of Toronto © Copyright by Reid Gallant 2017 i Alpha-dystroglycan Plays Functional Roles in Platelet Aggregation and Thrombus Growth Reid Gallant Master of Science Department of Laboratory Medicine and Pathobiology University of Toronto 2017 ABSTRACT Fibrinogen (Fg) and von Willebrand factor (VWF) have been considered essential for platelet adhesion and aggregation. However, platelet aggregation still occurs in mice lacking Fg and/or VWF but not β3 integrin, suggesting other, unidentified αIIbβ3 integrin ligand(s) mediate platelet aggregation. Through screening published platelet proteomics data, we identified a candidate, alpha-dystroglycan (α-DG). Using Western blot and flow cytometry, I found α-DG is expressed on platelets. Using aggregometry, I observed that antibodies against α-DG or its N- terminal Laminin-binding site, decreased platelet aggregation induced by various platelet agonists in both platelet-rich plasma and gel-filtered platelets. These antibodies also decreased platelet adhesion/aggregation in perfusion chambers independent of α-DG-Laminin interaction. Using laser injury intravital microscopy and carotid artery thrombosis models, we further found that these anti-α-DG antibodies decreased thrombus growth in vivo. Our results showed that α- DG may form an α-DG-fibronectin complex that binds to αIIbβ3 integrin, contributing to platelet adhesion/aggregation, and thrombosis growth. ii Acknowledgements ―It helps a man immensely to be a bit of a hero-worshipper, and the stories of the lives of the masters of medicine do much to stimulate our ambition and rouse our sympathies‖ – Sir William Osler I will always be grateful to my MSc supervisor, Dr.
    [Show full text]
  • Coagulation Factors Directly Cleave SARS-Cov-2 Spike and Enhance Viral Entry
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437960; this version posted April 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. Edward R. Kastenhuber1, Javier A. Jaimes2, Jared L. Johnson1, Marisa Mercadante1, Frauke Muecksch3, Yiska Weisblum3, Yaron Bram4, Robert E. Schwartz4,5, Gary R. Whittaker2 and Lewis C. Cantley1,* Affiliations 1. Meyer Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 2. Department of Microbiology and Immunology, Cornell University, Ithaca, New York, USA. 3. Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. 4. Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. 5. Department of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, NY, USA. *Correspondence: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437960; this version posted April 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary Coagulopathy is recognized as a significant aspect of morbidity in COVID-19 patients. The clotting cascade is propagated by a series of proteases, including factor Xa and thrombin. Other host proteases, including TMPRSS2, are recognized to be important for cleavage activation of SARS-CoV-2 spike to promote viral entry. Using biochemical and cell-based assays, we demonstrate that factor Xa and thrombin can also directly cleave SARS-CoV-2 spike, enhancing viral entry.
    [Show full text]
  • Thrombin-Jmi
    THROMBIN-JMI - thrombin, topical (bovine) THROMBIN-JMI; THROMBIN-JMI PUMP SPRAY KIT; THROMBIN-JMI SYRINGE SPRAY KIT - thrombin, topical (bovine) THROMBIN-JMI SYRINGE SPRAY KIT - thrombin, topical (bovine) THROMBIN-JMI EPISTAXIS KIT - thrombin, topical (bovine) King Pharmaceuticals, Inc. ---------- THROMBIN, TOPICAL U.S.P. (BOVINE ORIGIN) THROMBIN-JMI® Thrombin, Topical (Bovine) must not be injected! Apply on the surface of bleeding tissue. DESCRIPTION The thrombin in Thrombin, Topical (Bovine Origin) THROMBIN-JMI® is a protein substance produced through a conversion reaction in which prothrombin of bovine origin is activated by tissue thromboplastin of bovine origin in the presence of calcium chloride. It is supplied as a sterile powder that has been freeze-dried in the final container. Also contained in the preparation are mannitol and sodium chloride. Mannitol is included to make the dried product friable and more readily soluble. The material contains no preservative. THROMBIN-JMI® has been chromatographically purified and further processed by ultrafiltration. Analytical studies demonstrate the current manufacturing process’ capability to remove significant amounts of extraneous proteins, and result in a reduction of Factor Va light chain content to levels below the limit of detection of semi-quantitative Western Blot assay (<92 ng/mL, when reconstituted as directed). The clinical significance of these findings is unknown. CLINICAL PHARMACOLOGY THROMBIN-JMI® requires no intermediate physiological agent for its action. It clots the fibrinogen of the blood directly. Failure to clot blood occurs in the rare case where the primary clotting defect is the absence of fibrinogen itself. The speed with which thrombin clots blood is dependent upon the concentration of both thrombin and fibrinogen.
    [Show full text]
  • Blood Coagulation Factor X Exerts Differential Effects on Adenovirus Entry Into Human Lymphocytes
    viruses Article Blood Coagulation Factor X Exerts Differential Effects on Adenovirus Entry into Human Lymphocytes James S. Findlay 1, Graham P. Cook 2 and G. Eric Blair 1,* ID 1 School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK; jsfi[email protected] 2 Leeds Institute of Cancer and Pathology, University of Leeds, St. James’s University Hospital, Leeds LS9 7TF, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-113-343-3128 Received: 5 December 2017; Accepted: 30 December 2017; Published: 3 January 2018 Abstract: It has been proposed that blood coagulation factors, principally factor X (FX), enhance the uptake of human adenovirus type 5 (Ad5) into cultured epithelial cells by bridging the viral hexon capsid protein and cell-surface heparan sulphate proteoglycans (HSPGs). We studied the effects of FX on Ad transduction of lymphoid cell lines (NK92MI, a natural killer cell line; Daudi, a B-cell line and Jurkat, a T-cell line) as well as primary peripheral blood lymphocytes (PBL) and HeLa epithelial cells using either replication-deficient Ad5, or a derivative in which the Ad5 fiber was replaced with that of another Ad type, Ad35, termed Ad5F35. PBL and NK92MI were resistant to Ad5 transduction. Transduction of Jurkat and Daudi cells by Ad5 was reduced by FX but without discernible effects on cell-surface Ad5 binding. FX reduced virus binding and transduction of all lymphoid cell lines by Ad5F35, as well as transduction of the T- and Natural Killer (NK)-cell populations of PBL. Flow cytometry analysis showed that all lymphoid cell lines were negative for HSPG components, in contrast to HeLa cells.
    [Show full text]
  • RIASTAP®, Fibrinogen Concentrate (Human) Lyophilized Powder for Solution for Intravenous Injection
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------------------CONTRAINDICATIONS ------------------------------------ These highlights do not include all the information needed to use RIASTAP • Known anaphylactic or severe systemic reactions to human plasma-derived products (4). safely and effectively. See full prescribing information for RIASTAP. ---------------------------------WARNINGS AND PRECAUTIONS---------------------------- RIASTAP®, Fibrinogen Concentrate (Human) • Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment (5.1). Lyophilized Powder for Solution for Intravenous Injection • Thrombotic events have been reported in patients receiving RIASTAP. Weigh the benefits of administration versus the risks of thrombosis (5.2). Initial U.S. Approval: 2009 • Because RIASTAP is made from human blood, it may carry a risk of transmitting ------------------------------------RECENT MAJOR CHANGES--------------------------------- infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent Indications and Usage (1) 06/2021 and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent (5.3). Dosage and Administration (2.2) 07/2020 -------------------------------------ADVERSE REACTIONS-------------------------------------- ----------------------------------INDICATIONS AND USAGE----------------------------------- • The most serious adverse reactions observed are thrombotic episodes (pulmonary RIASTAP, Fibrinogen
    [Show full text]
  • Urokinase and Urokinase Receptor in the Urinary Tract of the Dog Trina Racquel Bailey Louisiana State University and Agricultural and Mechanical College
    Louisiana State University LSU Digital Commons LSU Master's Theses Graduate School 2005 Urokinase and urokinase receptor in the urinary tract of the dog Trina Racquel Bailey Louisiana State University and Agricultural and Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses Part of the Veterinary Medicine Commons Recommended Citation Bailey, Trina Racquel, "Urokinase and urokinase receptor in the urinary tract of the dog" (2005). LSU Master's Theses. 1457. https://digitalcommons.lsu.edu/gradschool_theses/1457 This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Master's Theses by an authorized graduate school editor of LSU Digital Commons. For more information, please contact [email protected]. UROKINASE AND UROKINASE RECEPTOR IN THE URINARY TRACT OF THE DOG A Thesis Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College in partial fulfillment of the requirements for the degree of Master of Science In The Interdepartmental Program in Veterinary Medical Sciences through the Department of Veterinary Clinical Sciences by Trina Racquel Bailey BSc, Doctor of Veterinary Medicine Atlantic Veterinary College, University of Prince Edward Island, 2000 December 2005 To my husband John, who has been there to help me through it all. To my son Ewan, who makes everything worthwhile. To my family and family in law for all their love, help and support. To Dude, Bailey, Sarah, Scamp, Ellie, Abby, and all the other wonderful animals who have been there for me to love and have allowed me to learn.
    [Show full text]